Peer-Reviewed Literature Synthesis

NAFLD / MASH (Metabolic-Associated Steatohepatitis) Biomarker Atlas

Molecular alterations reported in NAFLD / MASH (Metabolic-Associated Steatohepatitis) compared to healthy controls, from peer-reviewed literature.

Literature Overview

Biomarkers below are included only where peer-reviewed literature explicitly reports the marker's direction in NAFLD / MASH (Metabolic-Associated Steatohepatitis) patients relative to a named comparison population — not inferred.

5
Curated markers
2
Categories

Searchable Alterations Database

Comparison populations are quoted as reported in the source literature (e.g. healthy controls, disease-matched patients).

Marker / TestDirectionCategoryvs. ComparisonClinical ContextKey Reference

Key References

Peer-Reviewed Literature

Liu et al. 2023

DOI: 10.3390/nu15081892 →
Peer-Reviewed Literature

Feldstein et al. 2009

DOI: 10.1002/hep.23050 →
Peer-Reviewed Literature

Padureanu et al. 2021

DOI: 10.3892/etm.2021.10790 →
Peer-Reviewed Literature

Liang et al. 2023

DOI: 10.1016/j.jhep.2023.04.025 →
Disclaimer: Educational synthesis of peer-reviewed literature only — not medical advice. Markers are drawn from published disease-vs-comparison-population studies; inclusion here does not imply diagnostic or clinical validation. Consult a qualified healthcare professional for interpretation.

Individual NAFLD / MASH (Metabolic-Associated Steatohepatitis) biomarker pages

Each NAFLD / MASH (Metabolic-Associated Steatohepatitis) marker has its own page with direction, comparison group, symptoms, test details, citation and FAQ. Browse all marker pages.

Hepatic

Other

Cite this page

Reusing these data? Please cite the tracker so others can find the source.

Open Source Medicine Foundation. (2026). Fatty Liver (NAFLD/MASH) Biomarkers: 5 Blood Tests & Lab Markers. Research Tracker. https://research.opensourcemed.info/nafld-mash-metabolic-associated-steatohepatitis-biomarkers.html (accessed )

Weekly post-viral research digest

New peer-reviewed studies and trial activity across Long COVID, ME/CFS, PACVS, Lyme and Gulf War Illness, every week. Free, no spam.

Subscribe on Substack   Browse the digest archive · RSS